# Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma

> **NCT00017602** · PHASE3 · COMPLETED · sponsor: **Genta Incorporated**

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **BIOLOGICAL:** oblimersen sodium
- **DRUG:** dexamethasone

## Key facts

- **NCT ID:** NCT00017602
- **Lead sponsor:** Genta Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-12
- **Primary completion:** —
- **Final completion:** 2009-04
- **Target enrollment:** — (—)
- **Last updated:** 2014-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00017602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00017602, "Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00017602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*